FDA approves MSD’s Lipfendra as first oral PCSK9 inhibitor
FDA approves MSD’s Lipfendra as first oral PCSK9 inhibitor European Pharmaceutical Review
2026
FDA Approves Bioequivalent Olaparib in Across Previously Approved Cancer Indications
FDA Approves Bioequivalent Olaparib in Across Previously Approved Cancer Indications OncLive
How Does the FDA Approval of Risankizumab Impact Pediatric Psoriasis and PsA? With Amy Paller, MD
How Does the FDA Approval of Risankizumab Impact Pediatric Psoriasis and PsA? With Amy Paller, MD HCP Live